X

Trial Profile

An open-label extension study of AZP2006 at a known dose in patients with progressive-supranuclear-palsy

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 01 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ezeprogind (Primary)
Indications Progressive supranuclear palsy
Focus Therapeutic Use
Sponsors AlzProtect

Most Recent Events

01 Mar 2023 New trial record
16 Feb 2023 According to a Alzprotect media release, National Agency for the Safety of Medicines and Health Products (ANSM in French) and the Ethical Review Board (CPP in French) have given their approval for this extension study, which should start in March and will be open-label (i.e. all patients will receive AZP2006 at a known dose).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com